Mullani, a pioneer in positron emission tomography (PET) prototype development, has been recognized for his significant contributions to the field. He developed new innovations in PET designs and published the first validation of time-of-flight information in PET to improve image quality.
Henry VanBrocklin, a professor at the University of California, San Francisco, has been recognized for his decades-long research on novel radiopharmaceuticals and their applications in medical imaging. He is being honored with the prestigious Paul C. Aebersold Award for his contributions to nuclear medicine.
A new PET radiotracer called <sup> 18 </sup> F-Cholestify has been developed to visualize metabolic cholesterol clearance in the brain. The tracer successfully visualized brain cholesterol metabolism in rats, non-human primates, and humans, showing promising results for studying neurodegenerative diseases.
Researchers have developed a new PET model to quantify cardiac amyloidosis, allowing for more accurate diagnoses and monitoring. The study found that a two-tissue reversible compartment model is the best method for quantifying 18F-flutemetamol myocardial uptake.
The global nuclear medicine initiative addresses the need for standardized educational curriculums to train physicians in nuclear theranostics procedures. The report highlights the rapid evolution of theranostic radiopharmaceuticals and emphasizes the importance of continuing medical education to maintain expertise.
A new approach uses pretherapy imaging and dosimetry to personalize radioactive iodine treatment for refractory differentiated thyroid cancer patients. The method allows researchers to calculate personalized dosage of treatment, resulting in improved outcomes.
A novel imaging agent has been developed to non-invasively detect pulmonary fibrosis in its early stages. The agent targets extracellular matrix fibers and has shown significant uptake in lungs with pulmonary fibrosis, matching histological results. This breakthrough could lead to earlier detection and better monitoring of the disease.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.
A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
The Society of Nuclear Medicine and Molecular Imaging has issued new appropriate use criteria (AUC) for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The AUC covers four clinical categories of cancer, including breast cancer, skin cancer, and others, and addresses pediatric considerations.
A new nuclear medicine therapy has been shown to cure human non-Hodgkin lymphoma in an animal model, achieving a median survival of over 221 days. The treatment, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and showed favorable in vitro characteristics.
A blood draw can provide valuable information on the effectiveness of peptide receptor radionuclide therapy for neuroendocrine cancer patients. Blood-based biomarkers PPQ and NETest were found to predict PRRT response with 96% and 90% accuracy, respectively. The study opens possibilities for tailoring treatment to individual patients.
A literature review published by the Society of Nuclear Medicine and Molecular Imaging reveals how nuclear medicine brain imaging can help evaluate biological changes causing chemotherapy-related cognitive impairment. The findings confirmed the impact of chemotherapy drugs on cognitive function and highlighted the utility of various SP...
A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in nuclear medicine and molecular imaging. The authors discuss the strengths and weaknesses of current AI bots and highlight the benefits of collaborating with AI allies to cope with increasing workloads.
Current radiotherapy contouring guidelines often miss lesions in the prostate bed, leading to unnecessary tissue irradiation. PSMA PET mapping reveals that nearly a third of patients experience disease progression within 10 years after radical prostatectomy.
A novel lensless radiomicroscope has been developed for nuclear medicine imaging, offering high-resolution images of cells with a field of view over 500 times larger than current technology. The instrument is made from off-the-shelf parts and costs less than $100, making it accessible to more labs.
A new radiotracer successfully detected 100% of primary tumors across multiple cancer types, outperforming the current standard. It also showed promise in detecting lymph node and distant metastases, offering a promising alternative for diagnosis and treatment.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have published a new procedure standard/practice guideline for somatostatin receptor (SSTR) PET imaging in patients with neuroendocrine tumors. The guideline focuses on improved sensitivity, lower radiation dose, and sh...
A novel nuclear medicine imaging protocol, dual-phase amyloid PET, can assess both amyloid deposition and neurodegeneration with a single tracer injection, cutting costs and radiation exposure. The protocol was shown to be comparable in distinguishing patients with neurodegenerative diseases from controls.
A new study published in The Journal of Nuclear Medicine found that e-cigarette users have greater lung inflammation than cigarette smokers and non-smokers. The study used PET imaging to compare lung inflammation between e-cigarette users and cigarette smokers, revealing a unique inflammatory response in the lungs.
A study found that nearly half of Medicare patients with non-small cell lung cancer do not receive the recommended FDG PET/CT imaging prior to radiation therapy, leading to decreased overall and cancer-specific survival rates. This lack of adherence is linked to greater mortality rates.
A novel imaging agent, 68Ga-FAPI, has been shown to reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. This can help prevent costly follow-up and false management decisions for cancer patients.
PSMA PET/MRI successfully determines prostate cancer likelihood of return within two years after prostatectomy, aiding treatment decisions. High uptake in primary lesion and metastasis are associated with rapid recurrence.
A new study found that approximately three percent of all bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality. The research highlights the importance of early diagnosis and treatment, as well as potential automated detection methods using machine-learning algorithms.
A new molecular imaging radiotracer, <sup> 68 </sup> Ga-PentixaFor, demonstrates high image contrast in various cancers, including hematologic malignancies and small cell lung cancer. This agent targets the C-X-C motif chemokine receptor 4 (CXCR4), which is a predictor of poor prognosis in cancer patients.
A new study published in The Journal of Nuclear Medicine found that a PET/MRI machine learning model can reliably distinguish between patients with and without lymph node metastases. This breakthrough technology has the potential to eliminate sentinel lymph node biopsy, a common procedure for breast cancer treatment.
A new radiotracer, 18F-SMBT-1, detects overexpressed monoamine oxidase-B in cognitively unimpaired individuals with high beta amyloid levels, a key early sign of Alzheimer's disease. The agent shows increased binding to reactive astrocytes, suggesting its potential as a surrogate marker for detecting Alzheimer's disease.
Researchers successfully visualized systemic joint involvement in patients with autoimmune arthritis using ultra-low dose total body PET/CT scans. The scans showed high agreement with standard joint-by-joint rheumatological evaluations and a moderate to strong correlation with rheumatological outcome measures.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A new study shows that PSMA PET/CT imaging can change treatment plans for nearly 50% of patients with prostate cancer recurrence after radical prostatectomy. The imaging technique detected disease in 46.9% of patients, leading to major changes in treatment plans, including recommendations for additional treatments.
The Journal of Nuclear Medicine publishes a first-hand account of daily nuclear medicine practice in Kyiv, Ukraine, where physicians face constant bombing and shelling. Despite the challenges, Dr. Kmetyuk expresses gratitude for international support and hope for the future of Ukrainian medical professionals.
The Journal of Nuclear Medicine has achieved an impact factor of 11.082, a 10% increase over last year's score of 10.057. This marks the highest impact factor in the journal's history, reflecting the growing importance of nuclear medicine as a whole.
A new SPECT imaging system performs scans 10-100 times faster than current systems, offering better image quality and increased patient throughput. The self-collimation concept improves traditional SPECT imaging by reducing scan time and radiation exposure.
A targeted radionuclide alpha therapy called 225Ac-DOTATATE has shown promising survival rates and an acceptable toxicity profile in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors. Minimal toxicities were noted after treatment.
Current guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to consider information from PSMA PET imaging. PSMA PET is effective in identifying recurrences partially or fully outside the clinical target volume, suggesting its value for therapy planning.
A new PET imaging agent, <sup>68</sup> Ga-FAPI-46, has been shown to predict the severity of cardiac remodeling after a heart attack by identifying active fibrosis. This biomarker has potential to aid in diagnosis and treatment selection for patients with heart failure.
A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study. The theranostic approach targets metabotropic glutamate receptor 1 (GRM1) found in many human solid tumors.
Cathy Sue Cutler, PhD, was elected vice president-elect of SNMMI, focusing on securing funding for nuclear medicine services. She aims to generate training opportunities for SNMMI members on theranostics and educate the public on the value of nuclear medicine.
Munir Ghesani, MD, has been elected as president of SNMMI for his commitment to improving patient access to nuclear medicine scans. He plans to address issues such as reimbursement and regulatory approvals to grow the field of nuclear medicine.
Dr. Simon R. Cherry received the 2022 Benedict Cassen Prize for his groundbreaking contributions to nuclear medicine instrumentation and molecular imaging. He was recognized for his pioneering advancements in small-animal PET, PET/MRI hybrid imaging, and total-body PET.
Schwaiger received the SNMMI Georg Charles de Hevesy Nuclear Pioneer Award for his significant work in multimodal imaging and development of novel quantitative methods. His research interests included oncologic PET, thyroid endocrine, and neuroendocrine diseases.
Dmitry Beyder has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). As president-elect, Beyder will focus on guiding technologists out of the COVID-19 pandemic and strengthening the nuclear medicine technologist workforce and professional pipeline.
The SNMMI has launched the Mars Shot Fund to support innovative nuclear medicine and molecular imaging research. The fund aims to secure $100 million in funding and is currently at $600,000, following generous donations from individuals and organizations.
Helen Nadel, MD, FRCPC, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). She plans to address issues such as global communication, government and industry relationships, and diversity initiatives. With over 30 years of SNMMI membership, Nadel brings extensive experience to her role.
Krystle W. Glasgow has been elected as the 2022-23 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section, aiming to increase membership and enhance communication and educational offerings for nuclear medicine technologists.
Andrei Iagaru has received the inaugural Sam Gambhir Trailblazer Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to transformative research and exceptional mentorship. He is recognized for his work in PET/MRI, PET/CT, and targeted radionuclide therapy.
The Society of Nuclear Medicine and Molecular Imaging has recognized 15 new SNMMI Fellows, including past president Richard Wahl, MD, for their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach can help inform clinical decision-making early in the course of treatment.